Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration

16 Dec 2019

Abstract excerpt

Chimeric antigen receptor-engineered T cells targeting CD19 (CART19) provide an effective treatment for pediatric acute lymphoblastic leukemia but are less effective for chronic lymphocytic leukemia (CLL), focusing attention on improving efficacy. CART19 harbor an engineered receptor, which is delivered through lentiviral vector integration, thereby marking cell lineages and modifying the cellular genome by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31845905
DOI: 10.1172/jci130144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationPMID 31845905Read ↗

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell MalignanciesSemantic proximity Read ↗

Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapySemantic proximity Read ↗

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance.Semantic proximity Read ↗

Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell productsSemantic proximity Read ↗

Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantationSemantic proximity Read ↗

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling <i>CD19</i> splicing and CART-19 therapy resistanceSemantic proximity Read ↗

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapySemantic proximity Read ↗

Enhanced functionality of low-affinity CD19 CAR T-cells is associated with activation priming and a polyfunctional cytokine phenotypeSemantic proximity Read ↗

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemiaSemantic proximity Read ↗

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphomaSemantic proximity Read ↗

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignanciesSemantic proximity Read ↗

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.